Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.
Saved in:
| Title: | Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma. |
|---|---|
| Authors: | Ghannam JY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Harvard/MIT MD-PhD Program and Harvard Immunology PhD Program, Harvard Medical School, Boston, MA, USA., Bryan J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Molecular Diagnostics Laboratory, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Weiss J; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Kovarsky D; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel., Merrell D; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Messer C; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Schlueter-Kuck K; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Fell GG; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Lim-Fat MJ; Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada., Youssef G; Harvard Medical School, Boston, MA, USA.; Center for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Rahman R; Department of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA., Qin L; Department of Imaging, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA., Young GS; Departments of Radiology, Mass General Brigham, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA., Janes JT 3rd; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA., Van Orden M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA., Pfaff KL; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Gans A; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lin ES; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Huang RY; Departments of Radiology, Mass General Brigham, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA., Danysh BP; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Parida L; IBM Research, Yorktown Heights, NY, USA., Li S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA., Wen PY; Center for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Chiocca EA; Center for Tumors of the Nervous System, Mass General Brigham Cancer Institute & Department of Neurosurgery, Mass General Brigham, Boston, MA, USA., Neuberg D; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA., Ligon KL; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Department of Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Tirosh I; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel., Reardon DA; Center for Neuro-Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Getz G; Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Cancer Center and Department of Pathology, Massachusetts General Hospital, Boston, MA, USA., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. catherine_wu@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. catherine_wu@dfci.harvard.edu.; Broad Institute of MIT and Harvard, Cambridge, MA, USA. catherine_wu@dfci.harvard.edu. |
| Source: | Nature cancer [Nat Cancer] 2026 Jun 03. Date of Electronic Publication: 2026 Jun 03. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
